GURU.Markets stock price, segment price, and overall market index valuation
The company's share price uniQure N.V.
uniQure is a pioneering company in gene therapy. Its stock price is a story of both success (the first drug approved in Europe) and failure. Its price chart reflects high volatility and dependence on clinical trial results and competition.
Share prices of companies in the market segment - Dna
uniQure (QURE) is a pioneering gene therapy company focused on developing treatments for rare genetic diseases of the liver and central nervous system. We classify it as a "DNA technology company." The chart below reflects the dynamics of this cutting-edge and high-risk biotech sector.
Broad Market Index - GURU.Markets
uniQure is a pioneering company in gene therapy, having developed the first commercially approved drug in this field in Europe and the US. Its innovativeness earned it a place in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
QURE - Daily change in the company's share price uniQure N.V.
Shares of uniQure, a pioneer in gene therapy, are extremely volatile. Change_co measures the market reaction to clinical trial data and the commercial launch of its drugs. This metric is an essential component for building valuation models for companies at the forefront of genetics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
uniQure N.V. is a pioneer in gene therapy. This chart illustrates the extreme volatility of the biotech sector. A comparison with QURE, whose success depends on the approval and launch of its drugs, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
uniQure is a pioneering company in gene therapy, one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization uniQure N.V.
uniQure is a pioneer in the field of gene therapy. Its year-over-year performance reflects both the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs, as illustrated by the chart below.
Annual dynamics of market capitalization of the market segment - Dna
uniQure N.V. is a pioneering company in gene therapy. It has already launched the first drug for the treatment of hemophilia B. The chart shows how the market views the commercial potential of its approved drug and its scientific platform for developing new gene therapies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
UniQure, a pioneer in gene therapy, is a high-risk, high-potential story. Its stock price is entirely dependent on clinical trial results. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become the new standard for treating rare diseases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization uniQure N.V.
The performance of uniQure, a pioneer in gene therapy, depends on its product cycle. The monthly fluctuations on the chart reflect the commercial launch of its hemophilia B drug, the success of which will determine the validation of the potential of its entire technology platform.
Monthly dynamics of market capitalization of the market segment - Dna
uniQure is a pioneer in gene therapy, having developed and commercialized the world's first approved drug in this class. The company focuses on the treatment of rare liver and central nervous system diseases. The chart below reflects investor sentiment in the cutting-edge gene therapy sector, where uniQure holds pioneering status.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
uniQure is a company at the forefront of gene therapy. Its shares move not in sync with the market, but rather with laboratory news and regulatory decisions. Each clinical trial report can trigger a rise or fall, making its performance a reflection of investors' faith in scientific breakthroughs, not economics.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization uniQure N.V.
uniQure is a pioneer in gene therapy. The company's weekly stock price reflects both high hopes and risks. News about clinical trials, drug approvals, and manufacturing processes are causing sharp and significant price movements.
Weekly dynamics of market capitalization of the market segment - Dna
uniQure is a pioneer in gene therapy. Comparing its weekly performance with the broader biotech sector only highlights its uniqueness. The chart shows how news of clinical trials or drug approvals drives its stock price up or down, completely ignoring market and competitor movements.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of uniQure, a gene therapy pioneer, exist in a reality parallel to the stock market. Their weekly performance isn't a reaction to the Fed, but rather the results of clinical trials. A chart comparing them to the S&P 500 clearly demonstrates this disconnect: shares can soar on a day when the overall market is falling, and vice versa.
Market capitalization of the company, segment and market as a whole
QURE - Market capitalization of the company uniQure N.V.
UniQure's market capitalization is the saga of a gene therapy pioneer. The company's timeline reflects its long and arduous journey, including receiving the first approval for a gene therapy in the Western world. Its volatility is a story of scientific breakthroughs, clinical failures, and investor faith in the potential to treat rare diseases at the DNA level.
QURE - Share of the company's market capitalization uniQure N.V. within the market segment - Dna
uniQure is a pioneer in gene therapy, having developed the first commercially approved drug in this field in the Western world. Its market share reflects its leadership and decades of experience treating rare genetic diseases. The chart below shows the weight of this veteran at the forefront of biotechnology.
Market capitalization of the market segment - Dna
uniQure is a pioneer in gene therapy, having developed the first approved drug in this category in the Western world. The chart below shows the overall market capitalization of the DNA technology sector. Its volatility demonstrates the high stakes: trial failures can send shares plummeting, while the success of a single drug can generate billions.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows one of the pioneers of gene therapy. uniQure received approval for one of the most expensive drugs in the world. Its market cap is a dramatic story of scientific breakthroughs, commercial challenges, and attempts to prove that a single treatment can be cost-effective.
Book value capitalization of the company, segment and market as a whole
QURE - Book value capitalization of the company uniQure N.V.
For uniQure, a pioneer in gene therapy, book value is its production capacity for gene therapy drugs and its vast intellectual capital. This represents the scientific and material foundation for creating unique medicines. The chart shows how the commercialization of the first approved drug and investments in R&D generated the company's capital.
QURE - Share of the company's book capitalization uniQure N.V. within the market segment - Dna
uniQure is a pioneer in gene therapy with an approved drug. Its uniqueness lies in its own cutting-edge manufacturing facilities. The chart shows the proportion of the complex and expensive physical infrastructure required for commercial gene therapy production that the company controls.
Market segment balance sheet capitalization - Dna
Developing gene therapy, like uniQure's, is a highly research-intensive and capital-intensive process. Creating a commercial drug requires complex and expensive manufacturing facilities, making it a heavyweight among biotech companies.
Book value of all companies included in the broad market index - GURU.Markets
UniQure's book value is a unique combination of assets: cutting-edge laboratories, intellectual property in gene therapy, and one of the world's first commercial manufacturing sites for this type of drug. These assets reflect its status as an industry pioneer. The chart shows the physical scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - uniQure N.V.
uniQure is a gene therapy pioneer with an already approved drug. Its market capitalization is many times greater than its book value, as the market values not its laboratories but the potential of its entire scientific platform and future drugs, which could be worth billions.
Market to book capitalization ratio in a market segment - Dna
uniQure is a pioneer in gene therapy with an approved drug. Its valuation on this chart reflects both current sales and the potential for future developments. This represents a high premium to book value, which investors are paying for its unique scientific expertise and patent portfolio.
Market to book capitalization ratio for the market as a whole
uniQure is a pioneering company in gene therapy, having received approval for one of the first drugs in this field. Its valuation is based on the commercial success of its already approved product and the potential of its other developments. This metric for uniQure reflects how the market values the transition from clinical to commercial development in this revolutionary field of medicine.
Debts of the company, segment and market as a whole
QURE - Company debts uniQure N.V.
uniQure, a pioneer in gene therapy, spends heavily on R&D, funding it through partnerships, equity, and debt. For a company whose success depends on the outcome of multi-year clinical trials, access to capital is critical. This chart shows how uniQure is investing in technologies that have the potential to transform medicine.
Market segment debts - Dna
uniQure is a pioneer in gene therapy, one of the first companies to receive approval for such a drug in Europe and the US. Despite scientific success, commercialization and development of new treatments require significant resources. This chart shows how the company manages its capital, including debt, to finance production and expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio uniQure N.V.
uniQure N.V. is a pioneer in gene therapy, the development and approval process for which is extremely costly and lengthy. The company is often forced to raise debt to finance clinical trials and research. This chart illustrates its reliance on debt capital, highlighting the high financial risks involved in commercializing its innovative treatments.
Market segment debt to market segment book capitalization - Dna
uniQure is a pioneer in gene therapy. Developing such complex treatments is a lengthy and extremely expensive process. This chart shows how the company finances its cutting-edge research. It compares its debt structure, critical to survival, to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare diseases. This is an extremely capital-intensive field, where it takes years from idea to commercial product. How does the company finance its expensive research? This graph of total debt in the economy helps us understand how typical or risky its reliance on debt is for the innovative sector.
P/E of the company, segment and market as a whole
P/E - uniQure N.V.
uniQure is a pioneer in gene therapy, having developed the first commercially approved drug in this category in Europe and the US. This chart shows how investors value its complex technology platform and development pipeline. The high and volatile valuation reflects both the company's enormous potential and the risk of clinical failure.
P/E of the market segment - Dna
uniQure is a pioneer in gene therapy, having developed and received approval for a first-of-its-kind drug for hemophilia B. The company is focused on treating rare genetic diseases. This chart shows the average valuation for the DNA technology sector, helping to understand the market premium placed on breakthrough scientific advances.
P/E of the market as a whole
uniQure is a pioneer in gene therapy, already having launched drugs to market. Does the company's valuation reflect the general investor appetite for biotech, as measured by this chart? Or does it reflect a unique belief in its manufacturing platform and its ability to commercialize complex and expensive treatments, regardless of market cycles?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company uniQure N.V.
uniQure is a pioneer in gene therapy, developing treatments for rare genetic diseases, particularly hemophilia B. This chart shows market expectations regarding the commercial success of currently approved drugs and the potential of future developments. Projected profits depend on the company's ability to translate science into blockbusters.
%20P%2FE%20uniQure%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-uniQure-N.V.&v=1772635814995 "Chart of the company's future (projected) P/E uniQure N.V.")
Future (projected) P/E of the market segment - Dna
uniQure N.V. is a pioneer in gene therapy, having developed the first commercially approved drug in this field for the treatment of a rare genetic disease. The company continues to expand its development pipeline. This chart shows average expectations for the biotech sector, allowing us to assess the market's confidence in the future success of uniQure's clinical programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772635815011 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
uniQure N.V. is a pioneer in gene therapy. The company has already launched drugs and continues development. Its valuation is a combination of current sales and future expectations. This market sentiment chart helps understand how much investors are willing to pay for the long-term growth potential inherent in uniQure's pipeline.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635815024 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit uniQure N.V.
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare diseases such as hemophilia. The company already has approved drugs. This chart shows the complex path from years of unprofitable research to its first commercial successes, reflecting both sales revenue and the continued high costs of research and development.
Profit of companies in the market segment - Dna
uniQure is a pioneer in gene therapy, developing treatments for rare diseases such as hemophilia B. This chart shows the financial health of the biotech sector. For uniQure, which already has an approved drug, it reflects not only the investment climate but also the healthcare system's ability to pay for expensive, innovative treatments.
Overall market profit
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare genetic diseases. The success of such companies depends on the overall economic situation, as reflected in the chart. During periods of rising corporate profits and investor optimism, biotech startups find it easier to attract capital for expensive research, turning scientific breakthroughs into commercial success.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company uniQure N.V.
uniQure N.V. is a pioneer in gene therapy, developing single-dose treatments for severe genetic diseases such as hemophilia. This graph represents analyst expectations regarding the commercial success of approved drugs and progress in developing new ones, which determines the company's future.
%20profit%20of%20the%20company%20uniQure%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-uniQure-N.V.&v=1772635815062 "Graph of future (projected) profit of the company uniQure N.V.")
Future (predicted) profit of companies in the market segment - Dna
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare genetic diseases. The company's future depends on the success of its clinical programs and the commercialization of its products. This chart reflects aggregate profitability forecasts for the entire biotech industry, giving investors an idea of the overall risk appetite and potential of the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772635815085 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
uniQure N.V. is a pioneer in gene therapy. The company's success depends primarily on scientific breakthroughs, not economic cycles. However, the general market forecast presented here influences investor sentiment and their willingness to invest in long-term and risky biotech developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635815102 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - uniQure N.V.
uniQure N.V. is a pioneer in gene therapy, developing and commercializing treatments for rare diseases. For a company whose revenue depends on the success of several innovative products, this chart is key. It illustrates the enormous premium investors are paying for each dollar of revenue, anticipating future blockbusters.
P/S market segment - Dna
uniQure N.V. is a pioneer in gene therapy, developing single-dose treatments for severe diseases. Its future revenue is dependent on successful clinical trials and drug approvals. This chart reflects investor confidence in the commercial potential of the biotech sector, providing context for assessing the prospects of uniQure's unique scientific platform.
P/S of the market as a whole
uniQure is a pioneer in gene therapy, having developed the first commercially approved drug in this field. The company targets the treatment of rare liver and central nervous system diseases. For a company whose value is built on future revenue from breakthrough technologies, this chart provides a striking contrast. It demonstrates how high investor expectations are for its scientific platform compared to its current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company uniQure N.V.
uniQure is a pioneer in gene therapy, having developed the first commercially approved drug in this field. For such an innovative company, valuation is based on the potential of its future products, not current sales. This chart demonstrates investors' confidence that uniQure's research and development will translate into successful commercial drugs.
%20P%2FS%20uniQure%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-uniQure-N.V.&v=1772635815161 "The graph of the company's future (projected) P/S uniQure N.V.")
Future (projected) P/S of the market segment - Dna
uniQure N.V. is a pioneer in gene therapy, developing and commercializing drugs to treat rare genetic diseases such as hemophilia B. The company's success depends on clinical results and approvals. This chart shows average revenue projections for the gene therapy sector, allowing one to assess how highly the market values uniQure's potential compared to its peers.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772635815172 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare diseases such as hemophilia B. This chart illustrates market expectations for future revenue. uniQure's success in commercializing its expensive but revolutionary treatments directly impacts investor confidence that biotechnology will become a key growth driver.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635815178 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales uniQure N.V.
This chart illustrates the revenue of uniQure N.V., a gene therapy pioneer developing treatments for rare genetic diseases. The company's current revenue primarily consists of payments from pharmaceutical partners and royalties. The dynamics in this chart reflect progress in the commercialization of its breakthrough technologies and the success of clinical trials.
Sales of companies in the market segment - Dna
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare genetic diseases. This chart shows the potential and current size of the gene therapy market. The commercialization of uniQure's products, such as the first approved gene therapy for hemophilia B, directly shapes this market, turning cutting-edge science into a tangible revenue stream.
Overall market sales
uniQure N.V. is a pioneer in gene therapy. The company's success depends on breakthrough research and its ability to attract capital to support it. The overall economic climate, reflected in this chart, influences the investment climate and the market's willingness to finance innovative but risky biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company uniQure N.V.
uniQure is a pioneer in gene therapy, developing drugs aimed at treating rare diseases. The company's future revenue forecast is based on expectations of successful clinical trials and regulatory approvals. This chart illustrates analysts' confidence in the commercial potential of its cutting-edge developments.
%20sales%20of%20the%20company%20uniQure%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-uniQure-N.V.&v=1772635815236 "Schedule of future (projected) sales of the company uniQure N.V.")
Future (projected) sales of companies in the market segment - Dna
uniQure is a pioneer in gene therapy, focused on treating rare diseases such as Huntington's disease. The company is at the forefront of biotechnology, where the potential is enormous, but the risks are also high. This chart illustrates the forecast for the entire gene therapy market, and uniQure's success depends on its ability to translate scientific research into commercial products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772635815251 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
uniQure N.V. is a pioneer in gene therapy, whose research requires significant and long-term investment. The overall economic situation, reflected in this chart, directly impacts the availability of venture capital. uniQure's successful fundraising demonstrates investor confidence in the future of biotechnology, even if overall market forecasts appear cautious.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635815264 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality uniQure N.V.
uniQure is a pioneer in gene therapy, developing treatments for rare diseases. Like many research-stage biotech companies, it incurs significant R&D expenses. This chart reflects its net losses—the price of innovation. It's a story of long-term investments in science that could revolutionize medicine.
Market segment marginality - Dna
#VALUE!
Market marginality as a whole
uniQure is a pioneer in gene therapy, having developed the first drug of its class approved in Europe. They target rare genetic liver and central nervous system diseases. This graph, showing average profitability, is an indirect factor for uniQure. Their success depends not on general market cycles, but on scientific breakthroughs capable of creating a product with colossal value.
Employees in the company, segment and market as a whole
Number of employees in the company uniQure N.V.
uniQure is a pioneer in gene therapy, one of the first companies to receive approval for its product. Its staff reflects its status as a commercial company, which requires balancing R&D, complex manufacturing, and sales. This graph shows the evolution from pure research to full-fledged operations.
Share of the company's employees uniQure N.V. within the market segment - Dna
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare diseases. This chart shows the company's share of the scientific community in its niche. In an industry where intellectual capital is king, this growth signals the expansion of research programs and strengthening of its leadership in one of the most complex areas of medicine.
Number of employees in the market segment - Dna
uniQure N.V. is a pioneer in gene therapy, developing treatments for rare diseases. This chart shows employment trends in one of the most advanced fields of biotechnology. The growing number of researchers and clinical trial specialists in this niche demonstrates significant progress in treating genetic disorders and the enormous potential that attracts talent and investment.
Number of employees in the market as a whole
uniQure is a pioneer in gene therapy, having developed the first commercially approved drug in this field. The company treats rare inherited diseases. This chart demonstrates how uniQure's breakthrough biotech innovations are shaping new knowledge-intensive industries and creating demand for highly qualified specialists in science and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company uniQure N.V. (QURE)
uniQure N.V. is a pioneer in gene therapy. This chart demonstrates the value of its deep intellectual capital. The company has an approved drug and a platform for future development. The chart shows that the market values not its current workforce, but the enormous value of its scientific research, manufacturing know-how, and patent portfolio per scientist.
%20of%20the%20company%20uniQure%20N.V.%20(QURE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-uniQure-N.V.-QURE&v=1772635815443 "Chart of market capitalization per employee (in thousands of dollars) of the company uniQure N.V. (QURE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
uniQure is a pioneer in gene therapy. Its market capitalization is based on its unique technology platform and the potential of its drug pipeline. This chart demonstrates the exceptionally high valuation of its intellectual property and future prospects per employee, which is typical of leading biotech companies.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772635815556 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
uniQure is a pioneer in gene therapy, having developed the first approved drug of its class in the Western world. The chart shows the valuation of a company with a unique scientific and manufacturing platform. Its high cost per employee reflects the value of its intellectual property, patents, and potential for developing treatments for rare diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635815583 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company uniQure N.V. (QURE)
uniQure is a pioneer in gene therapy, having received approval for one of the first commercial drugs in its class. This represents a transition from pure R&D costs to revenue generation. This graph illustrates a unique moment: how revenue from an extremely expensive but revolutionary drug begins to cover the costs of highly qualified personnel engaged in production and further research.
%20Chart%20uniQure%20N.V.%20(QURE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-uniQure-N.V.-QURE&v=1772635815589 "Company Profit Per Employee (in thousands of dollars) Chart uniQure N.V. (QURE)")
Profit per employee (in thousands of dollars) in the market segment - Dna
uniQure N.V. is a pioneer in gene therapy. They received approval for their first drug (Hemgenix) for the treatment of hemophilia B. This figure reflects a unique situation: a company with a very small staff (R&D and production) sells one of the most expensive drugs in the world (priced at over $3 million), which should lead to astronomical profits per employee.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772635815607 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
uniQure N.V. is a pioneer in gene therapy. They were the first to receive approval for a gene therapy in Europe and the US (Hemgenix, for the treatment of hemophilia B). This graph shows a turning point. After decades of R&D (losses per employee), it should reflect the extreme profitability of their very expensive (millions of dollars) drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635815629 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee uniQure N.V. (QURE)
uniQure is a pioneer in gene therapy, having developed the first approved drug in this field. This chart reflects the commercial success of its unique technologies. The growth in revenue per employee, especially after the launch of a new product, demonstrates the enormous value of its intellectual property and the ability of a small scientific team to generate significant revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-uniQure-N.V.-QURE&v=1772635815648 "Sales chart per company employee uniQure N.V. (QURE)")
Sales per employee in the market segment - Dna
uniQure is a pioneer in gene therapy, a company with expensive and complex developments. This chart measures how effectively their team of scientists and commercial specialists transforms scientific breakthroughs into a marketable product. It shows revenue per employee compared to other innovative companies in the gene therapy segment.
Sales per employee for the market as a whole
uniQure (QURE) is a pioneer in gene therapy, with an approved and commercialized drug. Unlike R&D startups, uniQure generates revenue. This chart demonstrates how effectively a small but elite team of scientists and specialists in the production of highly complex drugs generates revenue, which is critical for assessing scalability in biotech.
Short shares by company, segment and market as a whole
Shares shorted by company uniQure N.V. (QURE)
uniQure N.V. is a pioneer in gene therapy, with an approved treatment for hemophilia B. Despite this, the company faces enormous research costs. This chart shows investors' downside bets. They may doubt the commercial success of existing products or the success of future clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-uniQure-N.V.-QURE&v=1772635815760 "Short Shares Chart for the Company uniQure N.V. (QURE)")
Shares shorted by market segment - Dna
uniQure N.V. is a pioneer in gene therapy. They were the first to receive approval for a gene therapy drug in Europe and the US (for hemophilia B). This metric measures pessimism. "Short" here is a bet that their commercial launch will fail or that their pipeline (for example, for Huntington's disease) will fail in the clinic.
Shares shorted by the overall market
uniQure (QURE) is a pioneering gene therapy company. They received approval for the world's first gene therapy drug for hemophilia B. This chart highlights concerns about commercial success. Bears are betting that the drug (costing millions of dollars) will be too expensive for insurance systems, or that its long-term efficacy and safety will be questionable.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator uniQure N.V. (QURE)
uniQure is a pioneer in gene therapy. The stock is highly volatile and dependent on R&D. This chart can surge above 70 on positive trial data or FDA approvals. Oversold territory (<30) is often associated with research setbacks, regulatory delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-uniQure-N.V.-QURE&v=1772635815904 "RSI 14 indicator chart for the company's stock uniQure N.V. (QURE)")
RSI 14 Market Segment - Dna
uniQure (QURE) is a pioneer in gene therapy. They were the first to receive approval for gene therapy in Europe (Glybera) and the US (Hemgenix, for hemophilia B). The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is QURE's volatility a reflection of their platform, or is the entire sector overheated?
RSI 14 for the overall market
uniQure (QURE) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast QURE (uniQure N.V.)
uniQure N.V. is a pioneer in gene therapy, specializing in the treatment of rare liver and central nervous system diseases. The company received approval for the world's first gene therapy for hemophilia B. This chart shows analyst consensus. Their target prices are based on the commercialization success of this drug and the potential of other gene therapy programs in development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-QURE-uniQure-N.V.&v=1772635816068 "A chart showing analyst consensus forecasts for the expected stock price. QURE (uniQure N.V.)")
The difference between the consensus estimate and the actual stock price QURE (uniQure N.V.)
uniQure (QURE) is a gene therapy pioneer specializing in the treatment of rare liver and central nervous system diseases (such as Huntington's disease). This is a pure R&D bet. This chart shows analysts' assessments of their science. It measures the gap between the price and the consensus target, reflecting the enormous (but speculative) potential they see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-QURE-uniQure-N.V.&v=1772635816185 "A chart showing the difference between the consensus forecast and the actual stock price. QURE (uniQure N.V.)")
Analyst consensus forecast for stock prices by market segment - Dna
uniQure (QURE) is a pioneer in gene therapy. The company developed the first approved therapy for hemophilia B (Hemgenix). This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe in the commercial success of this highly complex and extremely expensive treatment technology.
Analysts' consensus forecast for the overall market share price
uniQure (QURE) is a pioneer in gene therapy. They are developing one-shot treatments for rare genetic diseases like hemophilia B. This is pure, high-risk science. This chart reflects the overall risk appetite in the market, demonstrating how willing investors are to finance capital-intensive biotech breakthroughs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index uniQure N.V.
UniQure is a gene therapy pioneer. Their business is R&D at the cutting edge of science, focused on treating rare genetic diseases (e.g., hemophilia B, Huntington's disease) with a single injection. This chart is a pure barometer of their science. It likely reflects not revenue, but the market's faith in their clinical trials, the value of their R&D platform, and their manufacturing know-how.
AKIMA Market Segment Index - Dna
uniQure (QURE) is a biotech pioneer in gene therapy; the Dutch company made history by receiving approval for the world's first gene therapy for hemophilia B (Hemgenix). This summary metric measures R&D. The graph shows the segment average. This benchmark: how does QURE's breakthrough (AAV) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
uniQure is a leader in gene therapy, having developed the first approved treatment for hemophilia B. The company aims to treat diseases at the genetic level. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such innovative early-stage biotech companies.
